advert
Angel News

Back to Homepage

23rd November 2020 - 0 comments

BGF invests in human cell products and services provider DefiniGEN

DefiniGEN, a provider of human cell products and services, has raised £3.25 million to accelerate its next phase of growth. This includes £2 million from BGF, the UK’s most active investor, alongside its existing consortium of investors led by 24Haymarket.

DefiniGEN is a spin-out from the University of Cambridge, creating highly predictive disease cell models for preclinical research and drug development. The process of bringing new drugs to market is arduous, expensive and blighted by a high failure rate. DefiniGEN’s models help the biopharma industry to respond to these challenges, enabling highly relevant information on potential new drug efficacy to be realised in an accelerated manner.

...

Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:

Name:

Email:

Comment:

Enter the characters in the image shown:



Back to Homepage